Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a cytokine that drives the
generation of myeloid cell subsets including neutrophils, monocytes, macrophages, and …

With the development and regulatory approval of immune checkpoint inhibitors and adoptive
cell therapies, cancer immunotherapy has undergone a profound transformation over the …

Fewer than 200 proteins are targeted by cancer drugs approved by the Food and Drug
Administration (FDA). We integrate Clinical Proteomic Tumor Analysis Consortium (CPTAC) …

Peptides cancer vaccines are designed based on the epitope peptides that can elicit
humoral and cellular immune responses targeting tumor‐associated antigens (TAAs) or …

Immunosuppression is a hallmark of pancreatic ductal adenocarcinoma (PDAC),
contributing to early metastasis and poor patient survival. Compared to the localized tumors …

Pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer, is
characterized by poor treatment response and low survival time. The current clinical …

Neoantigen vaccines are based on epitopes of antigenic parts of mutant proteins expressed
in cancer cells. These highly immunogenic antigens may trigger the immune system to …

The COVID-19 pandemic has elevated mRNA vaccines to global recognition due to their
unprecedented success rate in protecting against a deadly virus. This international success …

Cancer is a chronic disease, and it can be lethal due to limited therapeutic options. The
conventional treatment options for cancer have numerous challenges, such as a low blood …

The recent development of RNA‐based therapeutics in delivering nucleic acids for gene
editing and regulating protein translation has led to the effective treatment of various …